Buy Neuromidin solution intravenously and intramuscularly 5mg/ml 1ml No. 10 in pharmacies

Neuromidin is an anticholinesterase agent that has a direct effect on the functions of the central nervous system. It is used to treat various diseases of the nervous system, including those caused by injuries. Pharmacological action develops quickly. The drug is prescribed for adults and children over 14 years of age.

Nosological classification (ICD-10)

• F09 Organic or symptomatic mental disorder, unspecified
• G12.2 Motor neuron disease
• G37.9 Demyelinating disease of the central nervous system, unspecified
• G58 Other mononeuropathies
• G61 Inflammatory polyneuropathy
• G62 Other polyneuropathies
• G62.9 Polyneuropathy, unspecified
• G70 Myasthenia gravis and other neuromuscular junction disorders
• G92 Toxic encephalopathy
• G96.8 Other specified disorders of the central nervous system
• G96.9 Damage to the central nervous system, unspecified
• K59.8.0* Intestinal atony
• M79.2 Neuralgia and neuritis, unspecified

Compound

Pharmacodynamics

Neuromidin® has a direct stimulating effect on the conduction of impulses along nerve fibers, interneuronal and neuromuscular synapses of the central nervous system and the peripheral nervous system. The pharmacological action of Neuromidin® is based on a combination of two mechanisms of action: blockade of potassium channels in the membrane of neurons and muscle cells; reversible inhibition of cholinesterase at synapses.

Neuromidin® enhances the effect on smooth muscles of not only acetylcholine, but also adrenaline, serotonin, histamine and oxytocin.

Neuromidin® has the following pharmacological effects:

– improves and stimulates impulse conduction in the nervous system and neuromuscular transmission;

- enhances the contractility of smooth muscle organs under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride;

- improves memory, inhibits the progressive course of dementia.

In preclinical studies, Neuromidin® did not have teratogenic, embryotoxic, mutagenic, carcinogenic or immunotoxic effects, and did not affect the endocrine system.

Neuromidin, 10 pcs., 1 ml, 5 mg/ml, solution for intramuscular and subcutaneous administration

Approved by the Pharmacological Committee of the Russian Ministry of Health

INSTRUCTIONS (information for the patient) for the use of the drug NEIROMIDINUM

International nonproprietary name

Ipidacrine (9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline hydrochloride monohydrate).

Dosage form

Pills.

Compound

Ipidacrine 20 mg.

Excipients: lactose, potato starch, calcium stearate.

Description

White tablets. In appearance they must comply with the requirements of the Global Fund XI, issue 2, p. 154.

Diameter - 6.0±0.2 mm.

Height - 2.7±0.3 mm.

Pharmacotherapeutic group

Cholinesterase inhibitor, neuromuscular conduction stimulator/ATS - N07AAOO.

Pharmacological properties

Neuromidin is a reversible cholinesterase inhibitor and also has a direct stimulating effect on impulse conduction at the neuromuscular synapse and in the central nervous system due to blockade of potassium channels in the excitable membrane.

Neuromidin enhances the effect on smooth muscles of not only acetylcholine, but also adrenaline, serotonin, histamine and oxytocin.

Neuromidin has the following pharmacological effects:

— restores and stimulates neuromuscular transmission;

- restores the conduction of impulses in the peripheral nervous system, disturbed due to the influence of various factors (trauma, inflammation, exposure to local anesthetics, some antibiotics, potassium chloride and other factors);

- enhances the contractility of smooth muscle organs under the influence of all agonists, with the exception of potassium chloride;

- moderately stimulates the central nervous system;

- improves memory and learning.

The drug does not have teratogenic, embryotoxic, mutagenic and carcinogenic, as well as allergenic or immunotoxic effects. The drug does not have a negative effect on the endocrine system.

After oral administration, Neuromidin is rapidly absorbed. The maximum concentration in the blood is observed after one hour. From the blood, Neuromidin quickly enters the tissues, and in the stabilization stage only 2% of the drug is found in the blood serum. Elimination of Neuromidin occurs through the kidneys, as well as extrarenally (biotransformation, secretion in bile). Only 3.7% of Neuromidin is excreted unchanged. This indicates the rapid metabolism of Neuromidin in the body.

Indications for use

Neuromidin is used in adults for diseases of the peripheral nervous system (neuritis, polyneuritis and polyneuropathy, polyradiculoneuropathies, myasthenia gravis and various myasthenic syndromes); bulbar paralysis and paresis, in the recovery period with organic lesions of the central nervous system, accompanied by motor disorders; in complex therapy of demyelinating diseases, with intestinal atony.

Contraindications

The use of Neuromidin is contraindicated in cases of epilepsy, extrapyramidal diseases, angina pectoris, severe bradycardia, bronchial asthma, individual hypersensitivity to the drug, vestibular disorders, peptic ulcer in the acute stage.

Use of the drug during pregnancy and lactation

Neuromidin penetrates well into all tissues of the body, increases the tone of the uterus and can cause premature birth, so it is not recommended to use the drug during pregnancy. The drug is used for weak labor. Contraindicated during breastfeeding.

Directions for use and doses

Neuromidin is used orally 1-3 times a day. A single dose of the drug is 10–20 mg (0.01–0.02 g) (0.5–1 tablets). For lesions of the peripheral nervous system, myasthenia gravis and myasthenic syndromes, the drug is prescribed orally at 10–20 mg (0.01–0.02 g) 1–3 times a day for 1–2 months. For short-term courses of treatment of patients with severe disorders of neuromuscular transmission, a single dose can be 20–40 mg (0.02–0.04 g) orally (1–2 tablets) 5–6 times a day.

For the treatment and prevention of intestinal atony, 20 mg (0.02 g) is prescribed 2-3 times a day for 1-2 weeks. If the next dose has not been taken, then continue the course of treatment at the previously prescribed doses. If necessary, you should consult your doctor.

special instructions

The drug increases the muscle tone of the uterus and can cause premature labor. Prescribe with caution for gastric ulcers, thyrotoxicosis, and diseases of the cardiovascular system.

Neuromidin penetrates well into tissues and organs, including the brain, and can have a sedative effect. Therefore, persons using Neuromidin should be careful when working with machinery. During treatment you should not drink alcohol.

Drug interactions

The drug enhances the sedative effect when interacting with central nervous system depressants. The action and side effects are enhanced when used together with other cholinesterase inhibitors and m-cholinomimetic drugs. In patients with myasthenia gravis, the risk of cholinergic crisis increases if Neuromidin is used simultaneously with other cholinergic drugs. Beta-blockers cause bradycardia if they were used before treatment with Neuromidin. When used simultaneously with alcohol, adverse side effects may increase.

Overdose

In case of Neuromidin poisoning or its relative overdose, m-anticholinergic blockers are used: atropine, cyclodol, etc.

Side effects

When using Neuromidin, hypersalivation, bradycardia, dizziness, nausea, vomiting, and allergic skin reactions (itching, rash) are possible. In these cases, reduce the dose or discontinue the drug. Hypersalivation and bradycardia can be reduced with m-anticholinergic blockers.

If during treatment with Neuromidin side effects are discovered that are not listed in the instructions, then it is necessary to inform the attending physician.

Manufacturer

JSC Olainsky Chemical-Pharmaceutical.

Address: st. Rupnicu 5, Olaine, LV-2114, Latvia.

Pharmacokinetics

After oral administration, intramuscular and subcutaneous administration, it is rapidly absorbed. Cmax in blood plasma is achieved 1 hour after oral administration and 25–30 minutes after intramuscular or subcutaneous administration. Binding to blood plasma proteins is 40–50% of the active substance. It quickly enters the tissues, the half-life of distribution is 40 minutes. Metabolized in the liver. It is excreted through the kidneys (mainly by tubular secretion and only 1/3 by glomerular filtration) and extrarenally (through the gastrointestinal tract). T1/2 of Neuromidin® when administered parenterally is 2–3 hours. After parenteral administration, 34.8% of the drug dose is excreted unchanged in the urine.

Arcoxia and Kagocel

Kagocel is an antiviral drug. Judging by the instructions for both Arcoxia and Kagocel, taking these drugs together is possible. Arcoxia can coexist with drugs of this pharmacological group, and Kagocel combines well with other antiviral drugs, immunomodulators, antibiotics and other drugs. But the combination of such means should be carried out by a qualified specialist. Independence in this matter and an arbitrary combination of medications can lead to negative consequences, poisoning and even death.

Contraindications

hypersensitivity to any of the components of the drug;

epilepsy;

extrapyramidal diseases with hyperkinesis;

angina pectoris;

severe bradycardia;

bronchial asthma;

mechanical obstruction of the intestine or urinary tract;

vestibular disorders;

peptic ulcer of the stomach or duodenum in the acute stage;

pregnancy (the drug increases the tone of the uterus);

lactation period;

children under 18 years of age (no systematic data on use).

With caution: for gastric and duodenal ulcers, thyrotoxicosis, cardiovascular diseases, as well as for patients with a history of obstructive diseases of the respiratory system or acute respiratory diseases.

Additionally for tablets

With caution: with lactase deficiency, lactose intolerance, lactose/isomaltose malabsorption syndrome, because the drug contains lactose.

Side effects

Caused by stimulation of m-cholinergic receptors: salivation, increased sweating, palpitations, nausea, diarrhea, jaundice, bradycardia, epigastric pain, increased secretion of bronchial secretions, bronchospasm, convulsions. Salivation and bradycardia can be reduced with m-anticholinergic drugs (atropine, etc.). Increased uterine tone, allergic skin reactions.

Rarely (after using higher doses), dizziness, headache, chest pain, vomiting, general weakness, drowsiness, and skin reactions (itching, rash) were observed. In these cases, reduce the dose or interrupt the drug for a short time (for 1–2 days). These side effects are observed in less than 10% of patients.

Arcoxia and alcohol

Due to the fact that the instructions do not directly prohibit combination with alcohol, the question of their compatibility naturally arises. The simultaneous use of non-steroidal anti-inflammatory drugs in combination with alcohol is undesirable due to the possible occurrence and intensification of side effects. Migraine, weakness, nausea and vomiting, allergic reactions, diarrhea, disorientation in space, kidney failure, increased load on the liver, etc. Not the most pleasant set, right? Arcoxia in combination with alcohol leads to deterioration of the gastrointestinal tract and poisoning and internal bleeding. The risk of myocardial infarction, increased blood pressure, and cardiovascular failure cannot be excluded. But there are still a couple of tips. You can start drinking alcohol only after the drug has been completely eliminated from the body, which means 24 hours after taking the last pill. This also works the other way around: you should not drink alcohol the day before taking Arcoxia.

Interaction

Neuromidin® enhances the sedative effect in combination with CNS depressants.

The action and side effects are enhanced when used together with other cholinesterase inhibitors and m-cholinomimetic drugs. In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases if Neuromidin® is used simultaneously with other cholinergic drugs.

The risk of developing bradycardia increases if β-blockers were used before starting treatment with Neuromidin®.

Neuromidin® can be used in combination with nootropic drugs.

Alcohol increases the side effects of the drug.

Reduces the inhibitory effect on neuromuscular transmission and the conduction of excitation along peripheral nerves by local anesthetics, aminoglycosides, and potassium chloride.

Modern spinal neurosurgery

Only modern minimally invasive surgical intervention (for example, video endoscopic microdiscectomy, or laser vaporization and nucleoplasty) can remove the hernia defect itself, or prevent its appearance in the case of protrusion. However, the Russian patient knows very well what surgery is. It hurts. This takes you out of normal life for a long time. It may be dangerous. There are so many such “buts” that surgery is considered the last type of treatment, when massage therapists, carboxytherapy sessions, manual therapists and kinesiotherapists stop helping.

Fortunately, in European countries, Israel, and the USA, the approach is completely different. If there are indications, the patient is operated on without pain, and often leaves the hospital on his own feet on the same day or the next. His quality of life is preserved. He is not prohibited from sitting for many days, and he is not forced to relieve himself while standing. Therefore, modern surgery is considered the best, fastest and most effective means of radical treatment. By the way, doctors in many Eastern European countries, for example, the Czech Republic, show excellent results in treating hernias surgically at fairly modest costs.

In Russia, they prefer not to immediately remove the hernial protrusion, but for many years to deal with its consequences and complications - to periodically treat inflammation, pain and swelling of the roots, which persistently arise again and again. And in this respect, the domestic patient resembles an unfortunate driver who, instead of finally changing a punctured tire, is forced to pump it up every half hour of driving. Only, unlike the driver, a patient who has been “treating” a hernia for a long time sometimes spends several times more money than the operation would cost.

Cervical hernia on MRI.

But even among the drugs for relieving swelling, back pain, and excess muscle tension, Neuromidin is not “listed.” However, it is sometimes prescribed for hernias, and is completely unjustified. The situation is aggravated by an unimaginably large number of sites that are written with stunning medical illiteracy. Because if there is a request “How to take Neuromidin for hernias,” then a helpful but illiterate article will immediately appear, which can even harm your health. How to take Neuromidin for hernias? Don't accept it at all. But first things first….

Directions for use and doses

Inside, s/c or i/m. Doses and duration of treatment are determined individually, depending on the severity of the disease.

Pills

Diseases of the peripheral nervous system:

- mono- and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies - 10-20 mg (0.5-1 tablet) 1-3 times a day. The course of treatment is from 1 to 2 months. If necessary, the course of treatment can be repeated several times with a break between courses of 1–2 months;

— to prevent myasthenic crises, in case of severe disorders of neuromuscular conduction, 1–2 ml (15–30 mg) Neuromidin® 1.5% solution for injection is administered parenterally for a short time, then treatment is continued with Neuromidin® tablets, the dose can be increased to 20–40 mg (1–2 tablets) 5 times a day.

Diseases of the central nervous system: bulbar paralysis and paresis, the recovery period of organic lesions of the central nervous system (traumatic, vascular and other origins), accompanied by motor and/or cognitive impairment - 10–20 mg (0.5–1 tablet) 2–3 times a day day. The course of treatment is from 2 to 6 months. If necessary, the course of treatment is repeated.

Treatment and prevention of intestinal atony - 20 mg (1 tablet) 2-3 times a day for 1-2 weeks.

Solution for intramuscular and subcutaneous administration

Diseases of the peripheral nervous system:

- mono- and polyneuropathy of various origins - subcutaneously or intramuscularly 5-15 mg 1-2 times a day, course - 10-15 days (in severe cases - up to 30 days); then treatment is continued with the tablet form of the drug;

- myasthenia gravis and myasthenic syndrome - subcutaneous or intramuscular 15-30 mg 1-3 times a day with further transition to the tablet form. The general course of treatment is 1–2 months. If necessary, treatment can be repeated several times with a break between courses of 1–2 months.

Diseases of the central nervous system:

— bulbar paralysis and paresis — subcutaneous or intramuscular 5–15 mg 1–2 times a day for 10–15 days; if possible, switch to tablet form;

- rehabilitation for organic lesions of the central nervous system - 10-15 mg intramuscularly 1-2 times a day, course - up to 15 days, then, if possible, switch to tablet form.

If the next dose was not taken on time, then it is not taken additionally.

The maximum daily dose is 200 mg.

Indications for use of the drug Neuromidin

Lesions of the peripheral nervous system - neuropathy, neuritis, polyneuritis, polyneuropathy, myelopolyradiculoneuritis, bulbar palsy and paresis; memory impairments of various origins (Alzheimer's disease and other forms of dementia in the elderly), mental retardation in children; lesions of the central nervous system of traumatic, vascular and other origins with impairments of memory, praxis, attention; myasthenia gravis and myasthenic syndromes; complex therapy of multiple sclerosis and other forms of demyelinating diseases of the nervous system; weakness of labor; intestinal atony.

Overdose

Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, constriction of the pupils, nystagmus, increased gastrointestinal peristalsis, spontaneous bowel movements and urination, vomiting, jaundice, bradycardia, intracardiac conduction disturbances, arrhythmias, decreased blood pressure, restlessness, anxiety, agitation, feelings of fear, ataxia, convulsions, coma, speech impairment, drowsiness, general weakness.

Treatment: symptomatic therapy is used, m-anticholinergic blockers are prescribed (atropine, cyclodol, metacin, etc.).

special instructions

There are no systematic data on the use of Neuromidin® in children.

Alcohol should be avoided during treatment (it increases the side effects of the drug).

Impact on the ability to drive a car or perform work that requires increased speed of physical and mental reactions. During treatment, you should refrain from driving a car, as well as engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Interaction with other drugs and alcohol

The use of Arcoxia does not replace the need to use other groups of medications, including antibiotics. But it's worth remembering the following:

• Before combining Arcoxia and other drugs, you should consult your doctor;
• Arcoxia enhances the effectiveness of anticoagulants and antiplatelet agents, lowering prothrombin time;
• reduces the effect of diuretics and antihypertensive drugs;
• if acetylsalicylic acid is used, then as a prevention of cardiovascular complications. But you should not get carried away, as gastric bleeding may be provoked;
• the compatibility of cyclosporines with Arcoxia enhances its nephrotoxic effect.

Release form

Tablets, 20 mg. 10 tablets each in blister packs made of PVC film and aluminum foil. 5 blister packs per cardboard pack.

Solution for intramuscular and subcutaneous administration, 5 mg/ml and 15 mg/ml. 1 ml of the drug in neutral glass ampoules (type I). 5 amp. in blister packs made of PVC film. 2 blister packs in a cardboard pack.

For the drug produced at SOPHARMA JSC, Bulgaria: 10 amp. in blister packs made of PVC film. 1 blister pack in a cardboard pack.